OncosphereExplore Cancer Insights and Innovations Today
Stay informed on cancer history, treatments, and the latest research breakthroughs and trials.
Read the latest →Cancer treatment paradigms
ConferenceESMO Congress 2026 in Madrid: what to watch
ESMO 2026 runs 23–27 October in Madrid. Presidential Symposia are on Saturday 24 and Sunday 25 October.
ApprovalsFDA oncology approvals, October 2026: a roundup
Pirtobrutinib in first-line CLL, tucatinib maintenance in HER2+ breast cancer, adjuvant atezolizumab for dMMR colon cancer and more.
ApprovalsDostarlimab gets FDA accelerated approval for MSI-H/dMMR locally advanced rectal cancer
On 19 October 2026 the FDA granted accelerated approval to dostarlimab for Stage II/III MSI-H or dMMR rectal cancer.
ConferenceAsco gi 2026
ASCO GI 2026 (San Francisco, 8–10 Jan): HERIZON-GEA-01, BREAKWATER FOLFIRI cohort and COMMIT.
TrialsDESTINY BREAST 11 TRIAL
Neoadjuvant T-DXd → THP raised pCR to 67.3% vs 56.3% with ddAC-THP in high-risk HER2+ early breast cancer, with less toxicity.
TrialsFlaura 2 trial
Osimertinib + platinum–pemetrexed: final OS 47.5 vs 37.6 months vs osimertinib alone in EGFR-mutant advanced NSCLC.
TrialsDEFI Trial: Nirogacestat for Desmoid Tumors
Phase 3 DeFi: oral γ-secretase inhibitor nirogacestat cut the risk of progression by 71% in progressing desmoid tumours.
Treatment paradigmsAdvanced Bladder / Urothelial cancer
Explore cancer history, treatments, and latest research.
Treatment paradigmsFirst-Line Systemic Therapy in Advanced Cancers
Choosing the right first-line systemic therapy is crucial in managing advanced cancers.
Historical Perspectives
Explore the evolving understanding of cancer through history, from early theories to modern advancements, shaping the way we diagnose, treat, and research this complex disease.
- 1940s — nitrogen mustard and Farber’s antifolate remissions in childhood leukaemia open the chemotherapy era.
- 1998 — trastuzumab (HER2) approved by the US FDA: targeted therapy arrives.
- 2001 — imatinib for CML: a pill that targets the driver (BCR-ABL).
- 2011 — ipilimumab: first checkpoint inhibitor to improve survival in melanoma.
- 2017 — first tissue-agnostic approval (pembrolizumab, MSI-H/dMMR).
- 2020s — antibody–drug conjugates, organ preservation with immunotherapy, ctDNA-guided care.
15
Trusted by Professionals
Expert Guidance
9
Posts
with sources
4
Guideline bodies
NCCN · ESMO · ASCO · ICMR
Empowering Cancer Awareness and Research
Oncosphere is dedicated to providing insightful information on cancer history, treatments, future trends, and the latest research to empower patients and families in their journey.
India registered an estimated 14.6 lakh new cancer cases in 2022 (ICMR–National Cancer Registry Programme projection; Sathishkumar et al., Indian J Med Res 2022). Every post here ends with what the evidence means for patients treated in Indian public and private hospitals.
Gallery
Explore visual insights on cancer research, treatments, and future trends.
General Medical Topics
Sharing thoughtful discussions on medical topics that matter to oncologists and their patients.
Coming up: vaccination during chemotherapy, febrile neutropenia at home, onco-cardiology basics and navigating CMCHIS / PM-JAY coverage for cancer care.
Get in Touch
We welcome your inquiries and feedback regarding cancer research, treatments, and our blog. Connect with us to share your thoughts.